Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia/small lymphocytic lymphoma

PURPOSE: Ibrutinib, a first-in-class, once-daily, oral inhibitor of Bruton’s tyrosine kinase, promotes apoptosis, and inhibits B-cell proliferation, adhesion, and migration. Ibrutinib has demonstrated single-agent efficacy and acceptable tolerability at doses of 420 and 840 mg in patients with chron...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Cancer Res
Autori principali: Coutré, Steven E., Furman, Richard R, Flinn, Ian W., Burger, Jan A., Blum, Kristie, Sharman, Jeff, Jones, Jeffrey, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Tran, Anh, Zhou, Cathy, Bilotti, Elizabeth, James, Danelle F., Byrd, John C., O’Brien, Susan
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6317338/
https://ncbi.nlm.nih.gov/pubmed/28073846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-1431
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi